• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYBoard
  • MYInsights
  • Strategy & Consulting
  • Contact Us
Select Page

Subsequent primary diagnosis of multiple myeloma after necrobiotic xanthogranuloma

by | Jul 1, 2024 | Publications

Dermatologie (Heidelb). 2024 Jul 1. doi: 10.1007/s00105-024-05388-7. Online ahead of print. NO ABSTRACT PMID:38949669 | DOI:10.1007/s00105-024-05388-7

Evaluation of interleukin-18 levels in patients affected by multiple myeloma and monoclonal gammopathy of undetermined significance: analysis and review of the literature

by | Jul 1, 2024 | Publications

Eur Rev Med Pharmacol Sci. 2024 Jun;28(12):3880-3887. doi: 10.26355/eurrev_202406_36465. ABSTRACT OBJECTIVE: Monoclonal gammopathy of undetermined significance (MGUS) is a preneoplastic disease that often precedes multiple myeloma. The multistep evolutionary pattern...

Causal associations between the gut microbiota and multiple myeloma: a two-sample Mendelian randomization study

by | Jul 1, 2024 | Publications

Front Nutr. 2024 Jun 14;11:1400116. doi: 10.3389/fnut.2024.1400116. eCollection 2024. ABSTRACT BACKGROUND: Previous observational studies have indicated a potential association between the gut microbiota and multiple myeloma (MM). However, the relationship between the...

Beyond the mouth: Uncovering non-secretory multiple myeloma through oral symptoms

by | Jul 1, 2024 | Publications

Imaging Sci Dent. 2024 Jun;54(2):211-220. doi: 10.5624/isd.20230257. Epub 2024 Apr 1. ABSTRACT Non-secretory multiple myeloma (NSMM) is a rare cancer of plasma cells characterized by the absence of detectable monoclonal M protein in the blood or urine. A 57-year-old...

Clinico-Pathological Profiles of Multiple Myeloma Patients in a Tertiary Care Hospital

by | Jun 30, 2024 | Publications

Mymensingh Med J. 2024 Jul;33(3):840-847. ABSTRACT Multiple myeloma (MM), mature B-cell lineage neoplasm, is characterized by abnormal clonal proliferation of plasma cells and presence of monoclonal protein (M protein). The study was conducted to reveal presenting...

Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management

by | Jun 29, 2024 | Publications

Am J Hematol. 2024 Jun 28. doi: 10.1002/ajh.27422. Online ahead of print. ABSTRACT DISEASE OVERVIEW: Multiple myeloma accounts for approximately 10% of hematologic malignancies. DIAGNOSIS: The diagnosis requires ≥10% clonal bone marrow plasma cells or a biopsy proven...
« Older Entries
Next Entries »

Recent Content

  • Treatment of Multiple Myeloma in Patients Refractory to Daratumumab/Anti-CD38 Monoclonal Antibodies: A Systematic Review
  • Pharmacists Play an Essential Role in Bispecific Therapy for Multiple Myeloma
  • Implications of lymphocyte kinetics after chimeric antigen receptor T cell therapy for multiple myeloma
  • Multiple myeloma as a challenging multidimensional random process: a data-driven web-based application for treatment selection
  • Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes
  • Deep Responses in Smoldering Multiple Myeloma Linked to Improved Outcomes
  • Urine-free response criteria predict progression-free survival in multiple myeloma: a post hoc analysis of BMT CTN 0702
  • Deciphering response dynamics and treatment resistance from circulating tumor DNA after CAR T-cells in multiple myeloma
  • High WEE1 expression is independently linked to poor survival in multiple myeloma
  • Evaluation of anti-CD38 monoclonal antibody-based immunotherapy in multiple myeloma with renal insufficiency: a systematic review and meta-analysis
  • Facebook
  • X
  • Instagram
©2016-2024 MYELOMA360
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT